Ceribell deploys a cloud‑linked, portable electroencephalogram (EEG) device—the Ceribell Rapid Response EEG System—that can be applied quickly by any healthcare provider to assess brain waves in minutes and identify seizures and other conditions in emergency departments and intensive care units. The system delivers brain monitoring results within minutes and was first cleared by the FDA via 510(k) in 2017; it is commercially available in the United States. Ceribell is focused on making EEG widely available, more efficient, and more cost‑effective to improve diagnosis and treatment of neurological conditions for at‑risk patients. The company plans to leverage machine learning and easy EEG accessibility to address additional neurological indications beyond seizures and recently received Breakthrough Device Designation from the FDA for a delirium indication. Ceribell closed a $50 million equity financing to support ongoing commercial expansion across EDs and ICUs and to further develop its technology. The company is headquartered in Sunnyvale, California. Ceribell develops an FDA-cleared, point-of-care EEG system that uses real-time cloud computing and the proprietary Clarity™ machine learning algorithm to deliver rapid bedside seizure diagnosis. Its Ceribell EEG System received FDA 510(k) clearance in 2017 and is commercially available in the United States. The company is led by CEO and co-founder Jane Chao. Ceribell’s platform targets faster diagnosis in patients with suspected seizures, focusing on emergency departments and intensive care units. The company plans to use the new funding to further expand its commercial presence in EDs and ICUs globally. No revenue or user metrics were provided in the article. Ceribell develops a Rapid Response EEG System that uses a disposable headband and a mobile recorder to acquire and transmit EEG data to a HIPAA-compliant cloud portal for remote specialist review. The system is designed for bedside triage and can be set up in minutes by any healthcare provider, using a proprietary "Brain Stethoscope" feature that converts EEG signals to sound. Ceribell's EEG System received FDA 510(k) clearance in 2017 and is commercially available in the United States. The company is led by CEO Jane Chao, Ph.D. Ceribell plans to use the proceeds from its recent financing to expand commercialization of its system.

Total raised

$138M

Funding rounds

3

Latest round

Series C

Latest activity

Sep 2022